{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:17:43Z","timestamp":1791227863399,"version":"4.1.0"},"reference-count":21,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients completed 1 of 3 phase III baricitinib trials (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01711359\">NCT01711359<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01710358\">NCT01710358<\/jats:ext-link>\n                      , or\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01721057\">NCT01721057<\/jats:ext-link>\n                      ) and entered the long-term extension RA-BEYOND (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01885078\">NCT01885078<\/jats:ext-link>\n                      ), in which patients received once-daily 4 mg or 2 mg baricitinib. Across these trials, patients initially receiving methotrexate (MTX) or adalimumab (ADA) switched to baricitinib 4 mg at Week 52. Patients initially receiving placebo (PBO) switched to baricitinib 4 mg at Week 24. Radiographs were scored at baseline and Years 2, 3, 4, and 5. Change from baseline in van der Heijde modified total Sharp score (\u0394mTSS) was computed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 2125 of 2573 (82.6%) randomized patients entered RA-BEYOND; 1837 of 2125 (86.4%) entered this analysis. From Years 3 to 5, higher proportions of disease-modifying antirheumatic drug (DMARD)-na\u00efve patients on initial baricitinib (monotherapy or with MTX) had no progression vs initial MTX (\u0394mTSS \u2264 0 at Year 5: 59.6% baricitinib 4 mg; 66.2% baricitinib 4 mg + MTX; 40.7% MTX). Higher proportions of patients with inadequate response (IR) to MTX on initial baricitinib or ADA vs PBO had no progression (\u0394mTSS \u2264 0 at Year 5: 54.8% baricitinib 4 mg; 55.0% ADA; 50.3% PBO). Higher proportions of patients with conventional synthetic DMARD-IR on initial baricitinib 4 mg had less progression vs initial PBO or baricitinib 2 mg (\u0394mTSS \u2264 0 at Year 5: 66.7% baricitinib 4 mg; 58.2% baricitinib 2 mg; 60.0% PBO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral baricitinib maintained lower levels of radiographic progression than initial conventional synthetic DMARD or PBO through 5 years in patients with active RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.210346","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T08:21:37Z","timestamp":1631694097000},"page":"133-141","source":"Crossref","is-referenced-by-count":9,"title":["Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND"],"prefix":"10.3899","volume":"49","author":[{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Kartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"2022062401251337000_49.2.133.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.122"},{"key":"2022062401251337000_49.2.133.2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L"},{"key":"2022062401251337000_49.2.133.3","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500343260"},{"key":"2022062401251337000_49.2.133.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"2022062401251337000_49.2.133.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.611"},{"key":"2022062401251337000_49.2.133.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200038"},{"key":"2022062401251337000_49.2.133.7","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/rheumatology\/keaa476","article-title":"Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies","volume":"60","author":"van der Heijde","year":"2021","journal-title":"Rheumatology"},{"key":"2022062401251337000_49.2.133.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"2022062401251337000_49.2.133.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2022062401251337000_49.2.133.10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022062401251337000_49.2.133.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2022062401251337000_49.2.133.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2022062401251337000_49.2.133.13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000898"},{"key":"2022062401251337000_49.2.133.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"2022062401251337000_49.2.133.15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40744-020-00231-6","article-title":"Efficacy and safety of baricitinib in Chinese rheumatoid arthritis patients and the subgroup analyses: results from study RA-BALANCE","volume":"7","author":"Yang","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2022062401251337000_49.2.133.16","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2022062401251337000_49.2.133.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018457"},{"key":"2022062401251337000_49.2.133.18","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2022062401251337000_49.2.133.19","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/rheumatology\/keaa576","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study","volume":"60","author":"Smolen","year":"2021","journal-title":"Rheumatology"},{"key":"2022062401251337000_49.2.133.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143420"},{"key":"2022062401251337000_49.2.133.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T04:27:53Z","timestamp":1656044873000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,1]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.3899\/jrheum.210346"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210346","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]}}}